Contraindicated (one)bortezomib will boost the amount or impact of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Potent or moderate CYP2C19 inhibitors could improve mavacamten systemic exposure, causing heart failure due to systolic dysfunction. levoketoconazole will enhance the level or result of bortezomib by affecting hepatic/intestinal enzyme CYP3A4 m... https://repaglinide77654.widblog.com/81596837/considerations-to-know-about-cp-866087